|
1
|
Cătană CS, Neagoe I Berindan, Cozma V,
Magdaş C, Tăbăran F and Dumitraşcu DL: Contribution of the
IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
World J Gastroenterol. 21:5823–5830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geremia A, Biancheri P, Allan P, Corazza
GR and Di Sabatino A: Innate and adaptive immunity in inflammatory
bowel disease. Autoimmun Rev. 13:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glauben R, Batra A, Stroh T, Erben U,
Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M and
Siegmund B: Histone deacetylases: Novel targets for prevention of
colitis-associated cancer in mice. Gut. 57:613–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salim SY and Söderholm JD: Importance of
disrupted intestinal barrier in inflammatory bowel diseases.
Inflamm Bowel Dis. 17:362–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Veltkamp C, Anstaett M, Wahl K, Möller S,
Gangl S, Bachmann O, Hardtke-Wolenski M, Länger F, Stremmel W,
Manns MP, et al: Apoptosis of regulatory T lymphocytes is increased
in chronic inflammatory bowel disease and reversed by anti-TNFα
treatment. Gut. 60:1345–1353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maul J, Loddenkemper C, Mundt P, Berg E,
Giese T, Stallmach A, Zeitz M and Duchmann R: Peripheral and
intestinal regulatory CD4+ CD25(high) T cells in
inflammatory bowel disease. Gastroenterology. 128:1868–1878. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brand S: Crohn's disease: Th1, Th17 or
both? The change of a paradigm: New immunological and genetic
insights implicate Th17 cells in the pathogenesis of Crohn's
disease. Gut. 58:1152–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaser A, Zeissig S and Blumberg RS:
Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eastaff-Leung N, Mabarrack N, Barbour A,
Cummins A and Barry S: Foxp3+ regulatory T cells, Th17
effector cells, and cytokine environment in inflammatory bowel
disease. J Clin Immunol. 30:80–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaffen SL: An overview of IL-17 function
and signaling. Cytokine. 43:402–407. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dambacher J, Beigel F, Zitzmann K, De Toni
EN, Göke B, Diepolder HM, Auernhammer CJ and Brand S: The role of
the novel Th17 cytokine IL-26 in intestinal inflammation. Gut.
58:1207–1217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujino S, Andoh A, Bamba S, Ogawa A, Hata
K, Araki Y, Bamba T and Fujiyama Y: Increased expression of
interleukin 17 in inflammatory bowel disease. Gut. 52:65–70. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nielsen OH, Kirman I, Rüdiger N, Hendel J
and Vainer B: Upregulation of interleukin-12 and −17 in active
inflammatory bowel disease. Scand J Gastroenterol. 38:180–185.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valencia X, Stephens G, Goldbach-Mansky R,
Wilson M, Shevach EM and Lipsky PE: TNF downmodulates the function
of human CD4+CD25hi T-regulatory cells.
Blood. 108:253–261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Garra A and Vieira P: Regulatory T cells
and mechanisms of immune system control. Nat Med. 10:801–805. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh B, Read S, Asseman C, Malmstrom V,
Mottet C, Stephens LA, Stepankova R, Tlaskalova H and Powrie F:
Control of intestinal inflammation by regulatory T cells. Immunol
Rev. 182:190–200. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mottet C, Uhlig HH and Powrie F: Cutting
edge: Cure of colitis by CD4+CD25+ regulatory
T cells. J Immunol. 170:3939–3943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Galvez J: Role of Th17 cells in the
pathogenesis of Human IBD. ISRN Inflamm. 2014:9284612014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hansen R, Thomson JM, El-Omar EM and Hold
GL: The role of infection in the aetiology of inflammatory bowel
disease. J Gastroenterol. 45:266–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bettelli E, Carrier Y, Gao W, Korn T,
Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal
developmental pathways for the generation of pathogenic effector
TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mangan PR, Harrington LE, O'Quinn DB,
Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR and
Weaver CT: Transforming growth factor-beta induces development of
the T(H)17 lineage. Nature. 441:231–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu J and Paul WE: Heterogeneity and
plasticity of T helper cells. Cell Res. 20:4–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Veldhoen M, Hocking RJ, Atkins CJ,
Locksley RM and Stockinger B: TGFbeta in the context of an
inflammatory cytokine milieu supports de novo differentiation of
IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu CF: A review on the pharmacology of
Paeonia lactiflora and its chemical components. Zhong Yao Tong Bao.
10:43–45. 1985.(In Chinese). PubMed/NCBI
|
|
26
|
Zhang LL, Wei W, Wang NP, Wang QT, Chen
JY, Chen Y, Wu H and Hu XY: Paeoniflorin suppresses inflammatory
mediator production and regulates G protein-coupled signaling in
fibroblast-like synoviocytes of collagen induced arthritic rats.
Inflamm Res. 57:388–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He DY and Dai SM: Anti-inflammatory and
immunomodulatory effects of Paeonia lactiflora Pall., a traditional
chinese herbal medicine. Front Pharmacol. 2:102011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee B, Shin YW, Bae EA, Han SJ, Kim JS,
Kang SS and Kim DH: Antiallergic effect of the root of Paeonia
lactiflora and its constituents paeoniflorin and paeonol. Arch
Pharm Res. 31:445–450. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim ID and Ha BJ: The effects of
paeoniflorin on LPS-induced liver inflammatory reactions. Arch
Pharm Res. 33:959–966. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin J, Xiao L, Ouyang G, Shen Y, Huo R,
Zhou Z, Sun Y, Zhu X, Zhang J, Shen B and Li N: Total glucosides of
paeony inhibits Th1/Th17 cells via decreasing dendritic cells
activation in rheumatoid arthritis. Cell Immunol. 280:156–163.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu L, Wei W, Zheng YQ and Jia XY: Effects
and mechanisms of total glucosides of paeony on joint damage in rat
collagen-induced arthritis. Inflamm Res. 54:211–220. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Y, Ren K, Liang C, Yuan L, Qi X, Dong
J, Shen J and Lin S: Renoprotective effect of total glucosides of
paeony (TGP) and its mechanism in experimental diabetes. J
Pharmacol Sci. 109:78–87. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang Q, Ma X, Zhu DL, Chen L, Jiang Y,
Zhou L, Cen L, Pi R and Chen X: Total glucosides of peony
attenuates experimental autoimmune encephalomyelitis in C57BL/6
mice. J Neuroimmunol. 284:67–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao M, Liang GP, Tang MN, Luo SY, Zhang
J, Cheng WJ, Chan TM and Lu QJ: Total glucosides of paeony induces
regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation
in lupus CD4(+) T cells. Clin Immunol. 143:180–187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cao W, Zhang W, Liu J, Wang Y, Peng X, Lu
D, Qi R, Wang Y and Wang H: Paeoniflorin improves survival in
LPS-challenged mice through the suppression of TNF-α and IL-1β
release and augmentation of IL-10 production. Int Immunopharmacol.
11:172–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu GL, Li YC and Shen YJ: Inhibitory
effect of total glucosides of paeonia on the NF-κB/p65 protein
expression in paws of RA rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
26:1082–1084. 2010.(In Chinese). PubMed/NCBI
|
|
37
|
Zhang Y, Zhou R, Zhou F, Cheng H and Xia
B: Total glucosides of peony attenuates 2,4,6-trinitrobenzene
sulfonic acid/ethanol-induced colitis in rats through adjustment of
TH1/TH2 cytokines polarization. Cell Biochem Biophys. 68:83–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wirtz S, Neufert C, Weigmann B and Neurath
MF: Chemically induced mouse models of intestinal inflammation. Nat
Protoc. 2:541–546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alex P, Zachos NC, Nguyen T, Gonzales L,
Chen TE, Conklin LS, Centola M and Li X: Distinct cytokine patterns
identified from multiplex profiles of murine DSS and TNBS-induced
colitis. Inflamm Bowel Dis. 15:341–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zou Y, Li WY, Wan Z, Zhao B, He ZW, Wu ZG,
Huang GL, Wang J, Li BB, Lu YJ, et al: Huangqin-Tang ameliorates
TNBS-induced colitis by regulating effector and regulatory CD4(+) T
cells. Biomed Res Int. 2015:1020212015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bell CJ, Gall DG and Wallace JL:
Disruption of colonic electrolyte transport in experimental
colitis. Am J Physiol. 268:G622–G630. 1995.PubMed/NCBI
|
|
42
|
Scheiffele F and Fuss IJ: Induction of
TNBS colitis in mice. Curr Protoc Immunol Chapter. 15:Unit
152002.
|
|
43
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Himmel ME, Yao Y, Orban PC, Steiner TS and
Levings MK: Regulatory T-cell therapy for inflammatory bowel
disease: More questions than answers. Immunology. 136:115–122.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Baumgart DC and Sandborn WJ: Inflammatory
bowel disease: Clinical aspects and established and evolving
therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Strober W, Fuss IJ and Blumberg RS: The
immunology of mucosal models of inflammation. Annu Rev Immunol.
20:495–549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou L, Ivanov II, Spolski R, Min R,
Shenderov K, Egawa T, Levy DE, Leonard WJ and Littman DR: IL-6
programs T(H)-17 cell differentiation by promoting sequential
engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8:967–974.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ivanov II, McKenzie BS, Zhou L, Tadokoro
CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR: The orphan
nuclear receptor RORgammat directs the differentiation program of
proinflammatory IL-17+ T helper cells. Cell.
126:1121–1133. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tamboli CP: Current medical therapy for
chronic inflammatory bowel diseases. Surg Clin North Am.
87:697–725. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou J, Wu ZX, Yang JH, et al: Effect of
total glucosides of Paeony on TNBS-in duced experimental Colitis in
rats. Chin J Gastroenterol. 4:154–158. 2009.
|
